Specialty Pharmacy

Process could improve treatment of diseases such as hemophilia and cystic fibrosis.

Research could aid drug discovery.

Bill authorizes the VA to spend as much as $500 million for hepatitis C treatments.

For more than 25 years, the Midwest AIDS Training + Education Center has educated clinicians who provide care to patients infected with human immunodeficiency virus (HIV) and those at risk for HIV.

Intra-abdominal fat cells associated with the progression of Crohn's disease and ulcerative colitis.

Molecular partnership may generate much-needed new treatments for the disease.

Cost of premiums, deductibles, and copays listed as important factors in choosing health plans.

Agreement with Immune Design could expand the potential of immunotherapy through combination approaches.

Onsolis provides opioid tolerant patients with an alternative dosing option.

Compound targets latent HIV proteins without harming other parts of the body.

Drug reduced chorea and writhing movements in patients afflicted with the disease.

Ethicists worried trials will threaten scientific rigor and efficacy.

Screening evaluates a large number of cells used in cancer therapy.

States need to target specific populations affected by HIV outbreaks.

Research advances personalized cancer therapy.

Alliances with specialty pharmacies result in collaboration and knowledge exchange, while building trust and increasing visibility of partners' services.

Religion and spirituality can have a positive impact on cancer outcomes.

MS comorbidities increase the risk of early mortality.

FDA-approved drug is now a first-line treatment for select patients with EGFR non-small cell lung cancer.

New treatment approach many help control inflammation.

Comorbidities lead to more complex treatment and higher costs.

David Lassen, chief clinical officer at Prime Therapeutics, discusses changes in store for the field of specialty pharmacy in the coming years.

Additional benefit from dasabuvir and combination of ombitasvir/paritaprevir/ritonavir found in pretreated genotype 1b hepatitis C patients without cirrhosis.

Research may help to target which patients will respond to specific chemotherapy drugs.

Inhibiting oxygen sensor leads to a reduced spread of breast cancer throughout the body.

Majority of participants experienced no spontaneous joint bleeding episodes.

Hepatitis C drugs with high cure rates create new dilemma for people in need of transplantation.

Patient experiences complete remission after treatment with 2 immunotherapies.

Patient who make multiple trips to their general practitioner before getting a diagnosis are more likely to respond negatively to other aspects of their care.

Roche is seeking FDA premarket approval of its companion diagnostic test for AstraZeneca's investigational therapy for non-small cell lung cancer patients with an acquired resistant mutation.